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Abstract  
Objective: There has been a recent resurgence of interest in physical treatments for 
functional motor disorders (FMD) including Transcranial Magnetic Stimulation (TMS). This 
pilot study aimed to test the effectiveness of a single session of motor cortex TMS as a 
treatment for functional upper limb weakness. 
Methods: Ten subjects with a diagnosis of functional upper limb weakness were 
randomised to immediate (n=7) or delayed (3 months) (n=3) TMS treatment. Median age 
was 35 (range 23-52) and median symptom duration was 2.3 years (range 5 months – 20 
years). 46-70 single pulses were applied to the motor cortex at 120-150% motor threshold. 
We used a verbal protocol designed to standardized the effects of suggestion. Primary 
outcome measures were self-reported symptom severity, grip strength and tapping 
frequency immediately after treatment, and symptom severity and disability (SF-12 and 
Modified Rankin Scale (MRS)) after three months. 
Results: There was a small significant reduction in symptom severity immediately after 
treatment, but no improvement in grip strength or tapping frequency and no change in 
symptom severity, SF-12 or MRS three months after treatment. Small numbers precluded 
comparison of immediate treatment with delayed treatment. Four of eight subjects 
responding to three-month follow-up reported late-onset adverse effects.  
Conclusion: This pilot study suggests limited benefits for TMS as a one-off non-
neuromodulatory treatment for stable chronic outpatients. TMS may still have a role 
alongside more intensive multidisciplinary therapy input, or in patients with severe deficits 
where the possibility of normal movement can be hard to demonstrate. 
Trial registration: NCT02102906 
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Introduction 
There is a rich history of electrical treatments for functional motor disorders (FMD), but 
such techniques fell out of favour after the First World War [1]. The development of 
Transcranial Magnetic Stimulation (TMS) has led to resurgence of interest with recent 
studies suggesting effectiveness of motor cortex stimulation in treatment of FMD.  
 
A systematic review in 2014 identified ten studies of TMS for the treatment of FMD, 
treating 95 patients in total (78 with weakness)[2]. All but one study reported improvement 
after treatment [3,4], including in symptoms of long duration. For instance, in a study of 24 
patients with a median symptom duration of 2.8 years, 75% had an immediate 
improvement in symptoms with benefit sustained beyond a year [5]. Another small pilot 
study found no symptomatic treatment effect in 11 patients receiving repetitive TMS, 
although there was some transient increase in muscle strength.[6]  
 
Where TMS has shown beneficial effects in FMD, mechanisms are unclear, and 
heterogeneity of TMS protocols between studies (ranging from a single session of 30 
pulses[7] to 4000 pulses of rTMS daily for 4-12 weeks[3]) makes it difficult to test 
hypotheses. It has been suggested that TMS might cause neuromodulation, although 
good effects have been reported in studies using TMS regimes which would not be 
expected to cause lasting neuronal change. Others have suggested that placebo factors 
may be important.  
 
One compelling idea is that supraliminal motor cortex TMS can demonstrate movement in 
an apparently paralysed limb, demonstrating to the patient that a) pathways from brain to 
limb are intact and b) potential for movement and therefore recovery exists.[2] This theory 
can be understood in the context of a paradigm described by Edwards et al, in which 
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beliefs about movement exert a top-down influence on sensorimotor processing to 
produce symptoms of Functional Neurological Disorder.[8]   
 
The TMS protocols reported in other studies are often complex, involving multiple 
treatment sessions, or report retrospectively on TMS used primarily for diagnostic 
purposes. In particular all of those studies applied TMS at the same time as other 
potentially therapeutic interventions including explaining the diagnosis, or providing 
physical rehabilitation or psychological therapy. The largest study treated patients with a 
mean duration of symptoms 5 days with many paediatric patients.[4] The second largest 
study gave rehabilitation and explanation at the same time.[5] 
 
In contrast, this study aimed test the effectiveness of a simple TMS protocol without 
additional treatments alongside. This centre has previously reported positive experiences 
of using therapeutic sedation and demonstration of the Hoover’s sign to patients in order 
to demonstrate normal movement in functionally dystonic or weak limbs[9,10], and 
ultimately it was hoped that TMS treatment, via similar mechanism, might be a useful 
addition to the repertoire of treatments offered by this service.   
 
The intention of this pilot study, therefore, was to test the effectiveness of a single session 
of supraliminal TMS, as a means of demonstrating movement, as a treatment for 
functional upper limb weakness.   
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Methods 
Subjects were recruited from routine consultant neurology (JS) and neuropsychiatry (AC) 
clinics. Subjects met inclusion criteria who were between age 18 and 75 and had a 
functional upper limb weakness as part of functional neurological symptom disorder 
according to DSM-5 criteria on the basis of positive clinical features. Diagnosis was made 
by a Consultant Neurologist (JS, eight cases) and a Consultant Neuropsychiatrist (AC, two 
cases) both with expertise in Functional Disorders.  
 
Upper limb weakness was specified as the target symptom because the intention was to 
effect movement of a functionally weak limb, and the arm and hand areas of the motor 
cortex are more consistently accessible to superficial stimulation than the leg area which 
can be more difficult to stimulate because of its deeper central location.   
 
Subjects were excluded who: did not speak English, had dementia or learning disability, 
alcohol dependence (as assessed by AUDIT screening questionnaire[11]), psychosis, 
suicidal ideation or severe personality disorder, cardiac pacemaker or other metal implant) 
[12,13],  a history at any time since birth of epileptic seizure. Factitious disorder was also 
an exclusion criterion; although it is impossible to completely exclude factitious disorder, 
participants were excluded where there was suspicion of factitious disorder or malingering, 
such as evidence of an extreme discrepancy between observed and reported function or 
clear reasons for malingering such as ongoing litigation.  
 
The study received NHS Research Ethics Committee approval, and the trial was 
registered at www.clinicaltrials.gov (NCT02102906).  
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Participants signed a consent form after discussion with a researcher and provision of 
written information about the study, including explanation of the possible important role of 
placebo factors. Hospital Anxiety and Depression Scale (HADS) [14], Alcohol Use 
Identification Test (AUDIT) [11] and TMS safety questionnaires [12,13] were completed 
prior to randomisation. Subjects who consented to participate and met inclusion criteria 
were allocated a study number. A consultant not involved with the study used a 
computerised random number generator (http://www.randomization.com) to generate a 
randomised list of condition (immediate or delay) against study number, and this 
consultant was contacted by email to obtain the condition for each participant after 
consent was obtained.  
 
Baseline self-reported symptom severity, disability, illness and treatment beliefs were 
assessed by Short Form 12 (SF-12)[15], Modified Rankin Scale (MRS)[16] and a study-
specific pre-TMS questionnaire immediately after randomisation in those randomised to 
delay, who then received usual care for three months before attending for treatment. 
These measures were assessed on the day of treatment for all participants including those 
randomised to delay.  
 
Participants attended the University of Edinburgh Psychology Department on a single 
occasion between December 2014 and September 2015. As part of a separate study, 
each participant first completed a 30-minute set of neuropsychological tests of verbal 
response latencies to visual stimuli on a computer screen. After completing these tests, a 
standardised explanation about TMS was given to participants (Table 1). Primary outcome 
measures of disability (SF-12 and MRS) and self-reported symptom severity (5-point Likert 
Scale) were taken immediately before treatment. Secondary outcome measures of 
impairment in the affected upper limb were also taken immediately before treatment:  hand 
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grip strength in kg (tested using a hand dynamometer – best of three) and tapping 
frequency (maximum taps of the spacebar within ten seconds - best of three). Outcome 
measures were assessed by the doctor performing TMS, who was therefore not blinded to 
group allocation or treatment effect.  
 
A Magstim Rapid 2 magnetic stimulator was used with a round coil and foot switch. 
Single pulses were administered at no greater than 0.3 hertz. Motor threshold was 
estimated, pragmatically, as the strength of stimulation at which three out of five 
stimulations created a visible movement in the limb. The stimulation intensity was then 
gradually increased to 120-150% of motor threshold, as tolerated and guided by the 
participant, and a further 46-70 single pulses (variation reflecting patient preference) were 
administered in sets of 4-5 pulses 3-4 seconds apart, producing palpable and usually 
visible muscle jerks of the hand and/or arm.  
 
The verbal protocol and procedure is described in Table 1. This verbal protocol was used 
in order to standardise the effects of suggestion, and was similar to that used in a study of 
therapeutic sedation for functional dystonia.[9] 
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Table 1.  
 
Protocol for explanation and procedure of TMS treatment of functional movement 
disorder used in this study 
 
 Explanation that TMS is a standard diagnostic procedure that has been around for over 20 years and 
we are not using unusual strengths. There is no evidence that TMS causes any problems other than 
to people with epilepsy 
 Warning about electrical sensation on head 
 The procedure is for treatment not diagnosis  
 TMS is being given to explore whether producing movements through the machine may allow 
improvement in symptoms by 
o Normalization of the brain pathways that have been disrupted in functional disorder.  
o Giving the brain some new ‘feedback’ from the affected limb that could help restore function 
(biofeedback) 
o A form of suggestion or placebo 
 Movement may occur more after procedure as much as during it 
 An understanding that this is not going to be a repeated procedure 
 For patients with complete paralysis – 
o Consent for sensory stimulation including nailbed pressure 
o Discussion of how the patient would handle sudden recovery with family and friends (i.e. 
would they worry that others thought they had been feigning if they suddenly improved? If so 
anticipate strategies to compensate. e.g. "Family and doctors know you are not feigning", "If 
others happen to think this then that is a small price to pay for regained function"). 
 
Procedure 
 
 Patient seated in comfortable chair 
 Relative or friend may be present if they wish 
 Plenty of encouragement throughout. Use of humour, personal information from patient as appropriate 
 Find threshold using single coil 90mm on contralateral motor cortex to produce wrist or finger 
movement. Motor threshold should be taken as the intensity at which 3/5 stimulations produce visible 
movement.  
 If possible, stimulate leg movement using the round coil if the patient’s leg is affected 
 Apply at 125% of threshold, or higher if tolerated, to induce elbow/wrist/finger movements 
 Aim for at least 50 stimulations over a 30 minute period, carrying out 4-5 stimulations at a time 3-4 
seconds apart  
 Examples of comments to make during procedure 
o “Let’s see if we can get those automatic normal movements going again.” 
o “That was a good movement - let’s do that again.” 
o “How does it feel to see that movement?” – “Is it a good feeling?” 
o “Don’t fight the strange feeling of your arm/leg moving again.” 
 After a series of five stimulations, carry out power testing as a form of ‘physio’ to capitalize on any 
improvements during the procedure. Example movements include 
o Elbow flexion against resistance 
o Wrist flexion against resistance 
o Finger flexion against resistance 
o Knee flexion against resistance 
o Ankle plantar flexion against resistance 
 In patients with dense sensory loss (unusual) use sensory stimuli (which all should be consented prior 
to the procedure) include 
o Nail bed or sternal pressure 
o Induction of plantar or deep tendon reflexes 
 Continue for no longer than 30 minutes but shorter if the patient prefers to stop (check the patient is 
happy to carry on after each group of 4-5 stimuli) 
 If there is a dramatic improvement continue to reinforce movements after procedure.  
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The primary outcome measure of self-reported symptom severity was assessed 
immediately after treatment as part of a set of study-specific questionnaires which also 
included questions assessing participant perception of treatment effectiveness (‘How 
effective was TMS treatment for your symptoms?’), tolerability of treatment (‘How painful 
or uncomfortable was TMS treatment), and a checklist of adverse effects with space for 
free-text responses.  
 
Primary outcome measures of SF-12, MRS, and self-reported symptom severity were 
repeated three months after treatment together with a study-specific questionnaires 
including questions about treatment effectiveness and adverse effects.  
 
Statistical analysis was performed using SPSS v21. Shapiro-Wilk tests were performed to 
check data for normality; where normally distributed, paired samples t-tests were used to 
compare measures before and after treatment, and where data at one or both time-points 
was not normally distributed the Willcoxon Sign Rank test was used.  
 
Results 
Thirteen patients were recruited. One did not meet inclusion criteria, eight were 
randomised to immediate treatment and four to three-month delay; two withdrew before 
treatment and ten attended for treatment (seven immediately and three after delay).These  
10 patients had the following characteristics: 6 female, 4 male; median age 35 years 
(range 23-52); 9 right handed, 1 left handed; median duration of symptoms 2.3 years 
(range 5 months to 20 years); 6 left sided weakness, 4 right sided weakness; Mean HADS 
score 14.1 (range 2-29, SD 7.8)  SF-12 scores were similar before (mean±SD: PCS  
32.5±0.2, MCS 35.4±11.1) and after delay (PCS 35.1±10.3, MCS 43.3±11.0), and 
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MRS scores were similar before (2±1) and after delay (2±1). Clinical characteristics, 
comorbidities, prior investigations, and response of subjective symptom severity to 
treatment are presented in Table 2. The trial was terminated prematurely (the original 
intention being to recruit 40 participants) as a result of difficulties recruiting patients – the 
target condition of unilateral upper limb weakness being less frequent in clinics than was 
projected – and because the treatment as given did not seem effective. Small numbers 
precluded analysis of immediate vs delayed treatment.  
  
Table 2. Clinical characteristics and self-reported symptom severity before and after TMS. 
All patients were diagnosed and received detailed explanation and support from a specialist in functional disorders (neurologist (JS) or neuropsychiatrist ( AC); 
HADS, hospital anxiety and depression scale; HADS-A, anxiety subscale; HADS-D, depression subscale; SF-12, short-form 12 health survey; FDS, functional 
disorders specialist (consultant neurologist or neuropsychiatrist); severity scores 1-5 (1 ‘no weakness at all’, 2 ‘mild weakness’, 3 ‘moderate weakness’, 4 ‘severe 
weakness’, 5 ‘very severe weakness’); L=Left; R=Right 
Age Sex Han
ded
ness 
Functional 
symptoms 
Comorbidities Durati
on of 
arm 
weak
ness 
Relevant 
Medication 
Previous 
investigation
s 
Additional 
Previous 
treatment 
HADS 
score, 
(HADS-
A,  
HADS-D) 
Day of 
treatment  
SF12 PCS, 
MCS  /  
Modified 
Rankin 
Score 
Symptom 
severity 
pre-TMS 
1-5  
Symptom 
severity 
immediatel
y post-TMS 
1-5  
 
Symptom 
severity 
3 months 
post-TMS 
1-5 
SF12 / 
Modified 
Rankin 
Score 3 
months 
post-TMS 
48 M L  L arm / leg 
weakness, 
hemi-
anaesthesia 
Splenectomy, 
hypertension 
20 
years 
Sodium 
valproate, 
Gabapentin, 
Co-codamol, 
Amitriptyline,  
MRI brain and 
whole spine -
normal 
Outpatient 
specialist 
physiotherapy 
10 (5, 5) 
 
23, 53 / 3 4 3 4 18, 54 / 4 
39 M R L arm 
weakness, R 
leg 
weakness, 
intermittent 
dysarthria 
 5 
years 
Trazodone,  MRI brain - 
nonspecific 
white matter 
hyperintensitie
s.  
MRI whole 
spine -normal 
Outpatient 
specialist 
physiotherapy 
24 (9,11) 51, 25 / 3 4 4 4 30, 27 / 4 
41 F R L arm and 
leg 
weakness 
Right trigeminal 
neuralgia 
5 
month
s 
Gabapentin, 
Carbamazepi
ne, 
Dihydrocodei
ne, 
Paracetamol 
MRI brain - 
normal 
Inpatient 
specialist 
physiotherapy 
19 (9,10) 31, 40 / 3 2 2 Did not 
return 
follow-up 
questionn
aires.  
Did not 
return 
follow-up 
questionn
aires. 
41 F R L arm / hand 
weakness 
None 2.5 
years 
none X-ray and MRI 
wrist (reported 
normal) 
Physiotherapy 11 (5,6) 49, 54 / 1 4 4 4 37, 34 / 0 
23 F R R arm / leg 
weakness 
None 15 
month
s 
none MRI brain and 
cervical spine 
both normal 
 20 (13,7) 41, 30 / 4 4 4 Did not 
return 
follow-up 
questionn
aires. 
Did not 
return 
follow-up 
questionn
aires. 
25 F R R arm/ leg 
weakness, 
dissociative 
seizures,  
Migraine 12 
month
s 
Topiramate, 
Tramadol, 
Dihydrocodei
ne, Cyclizine 
MRI brain and 
whole spine 
normal 
Cognitive 
behavioural 
therapy for 
dissociative 
seizures 
14 (11,3) 31, 46 / 3 3 2 3 26, 49 / 2 
31 F R R arm / leg 
weakness 
Irritable bowel 
syndrome, mild 
depression. 
1 year 
9 
Mirtazapine MRI brain and 
lumbar spine - 
normal 
 13 (7,6) 36, 56 / 1 2 2 2 53, 44 / 1 
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month
s 
53 M R L arm / leg 
weakness 
Obstructive 
sleep apnoea, 
restless leg 
syndrome 
6 
years 
Ropinorole, 
Rabeprazole, 
Tramadol, 
Diazepam, 
Sertraline, 
Trazodone, 
plus,  
MRI brain -
nonspecific 
white matter 
hyperintensitie
s. MRI cervical 
spine - no 
relevant 
changes 
 2 (1,1) 23, 54 / 4 4 3 4 15, 55 / 4 
24 F R L arm / leg 
weakness,l 
visual 
impairment, 
dissociative 
seizures 
Bipolar affective 
disorder 
(euthymic at 
time of 
participation), 
slow-transit 
constipation, 
asthma. 
6 
years 
Lithium, 
Quetiapine, 
Cetirizine, 
Docusate, 
Linaclotide, 
Metacloprami
de, 
Mirabegron, 
Monteleukast
, 
Omeprazole, 
Peppermint 
oil, 
Procyclidine.  
MRI brain and 
spine - normal  
 Not 
complete
d 
25, 39 / 4 4 3 5 19, 43 / 4 
24 M R R arm / 
hand 
weakness 
None 2 
years 
none MRI shoulder 
and brachial 
plexus- no 
relevant 
abnormalities.
Neurophysiolo
gy normal.  
Physiotherapy.  9 (5,4) 42, 35 / 2 3 3 2 36, 59 / 2 
 
  
 
Prior to treatment, eight participants agreed or strongly agreed with the diagnosis of 
functional disorder; two strongly disagreed. Two participants believed TMS was ‘likely’ to 
help their weakness and eight were ‘uncertain’. No participants reported discomfort during 
the procedure. Two reported mild headache, three mild tingling and one mild difficulty 
concentrating immediately after TMS.  
 
Overall there was a significant reduction in self-reported symptom severity immediately 
after treatment (Willcoxon Signed Rank test p=0.05). Three participants reported a 
reduction in severity from ‘severe weakness’ to ‘moderate weakness’, and one participant 
from ‘moderate weakness’ to ‘mild weakness’. The remaining six participants reported no 
change in symptoms severity after treatment. Improvements in self-reported symptom 
severity were not reflected by objective measures, and there was no significant difference 
in grip strength (p=0.28) or tapping frequency (Willcoxon Signed Rank test p=0.89) after 
treatment. No patient reported delayed improvement after the treatment which had 
reversed by the time of follow up. 
 
Eight subjects (two after delayed treatment) returned three-month follow-up 
questionnaires. At three months, there were no significant differences compared with 
before treatment in the primary outcome measures of self-reported symptom severity 
(p=1), SF-12 PCS score (p=0.17), SF12 MCS score (p=0.91) or MRS score (Willcoxon 
Signed Rank test p=1).  
 
One participant, with functional hemianaesthesia, reported no improvement in weakness 
but 15-minute episodes of restored sensation every ten days during the three months of 
follow-up, and another reported improvement in handwriting.  
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Table 3. Outcome measures pre- and post- TMS treatment. Mean [range, SD], 
Median (range) 
 Day of treatment  (n=10) 3 months after 
treatment (n=8)1 Pre-treatment Immediately 
post-treatment 
‘How severe is your 
weakness at the moment?’  
(1=‘no weakness’ – 5=’very 
severe weakness’) 
3.4 [2-5, 0.8] 3.0 [2-4, 0.8] 3.5 [2-5, 0.8] 
Grip strength on 
symptomatic side, kg, 
before treatment / 
immediately after treatment  
10.9 [0-25, 8.1]  13.8 [0-30, 9]  
Maximum finger taps in 10 
seconds on symptomatic 
side, before treatment / 
immediately after treatment 
42.5 (0-59) 41 (0-53) 
 
 
Modified Rankin Scale 3 (1-4)  3 (0-4) 
SF-12 - PCS 34.9 [23-51, 11.4]  29.2 [18-53, 12.8] 
SF12 - MCS 45.3 [25-56, 11.2]  44.8 [27-55,10.5] 
 
However, four of the eight participants to return follow-up questionnaires reported adverse 
effects. One reported a severe headache arising on the day of treatment and persisting for 
24 hours, one “a thumping sore head for a few weeks”, another increased difficulty writing 
and opening things using the symptomatic hand for two days. Another reported a severe 
two-week long episode of dissociative regression: “forgetting simple things like what things 
tasted like, what people looked like and even how to do banking”.  
 
Discussion 
This pilot study of TMS as a treatment for FMD used a reproducible, pragmatic TMS 
protocol, and a pre-defined verbal protocol designed to standardise the effects of 
suggestion. All participants found treatment tolerable and there was a small immediate 
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improvement in weakness in around half the patients, but the improvements were not 
judged clinically significant nor were they sustained at three months.  
 
The largely negative results of this small study differ from the striking positive results 
previously reported elsewhere. There are a number of possible reasons for this.  
 
Most of our patients had already explored other treatment options and on the whole 
represent a group with chronic, stable, treatment-resistant symptoms, which may in part 
account for the poor response to treatment. By comparison one of the most positive 
studies of TMS used it in patients presenting acutely, many of whom may have improved 
anyway and in a way that would have been difficult to disentangle from the potentially 
positive effects of explanation and meeting a clinician interested in treating their 
disorder.[4]  
 
The second-largest previous study used TMS in combination with multidisciplinary 
rehabilitation, again casting doubt on its specificity.[5] In contrast, the TMS in this study 
was given in a single session, at a location and date remote from clinic follow-up, and no 
additional rehabilitative input was provided; we separated out the TMS from the other 
treatments and found that TMS alone was not effective.  
 
It may be that similar treatment given in the context of more intensive multidisciplinary 
therapy input might have had better and more synergistic effects. Ongoing therapy 
alongside TMS may, among other things, encourage ongoing confidence in the diagnosis 
of functional disorder (a prognostic factor) and by this mechanism increase the likelihood 
of sustained improvement after TMS; we were somewhat surprised to note that two of our 
participants ‘strongly disagreed’ with the diagnosis of functional disorder and also note that 
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only two believed that TMS was ‘likely to help’ their weakness with the remaining eight 
‘uncertain’, suggesting that confidence in the diagnosis had lessened since last clinic 
follow-up.  
 
It could be argued that transparent explanation of possible placebo effects associated with 
TMS might have reduced the strength of these effects. However, studies of open-label 
placebos have demonstrated positive placebo effects even where patients are aware that 
they were taking an inert substance.[17,18] We do not consider TMS to be an ‘inert’ 
treatment, only that placebo factors may contribute to treatment effects.   
 
Also of note, four of the eight participants in this study to return follow-up questionnaires 
reported significant side effects with delayed onset. Adverse effects of this nature have not 
previously been reported in studies of TMS for FMD. There are several possible 
mechanisms for the reported late-onset adverse effects. It is possible that the physical and 
unfamiliar nature of the sensations associated with TMS may bring about mild anxiety and 
a temporarily heightened awareness of bodily sensations. Post treatment anxiety and 
hyperarousal may have contributed to the period of dissociation reported by one 
participant after treatment. Although mild headache after TMS is normal, the two patients 
who reported prolonged headache perhaps demonstrate increased vulnerability to 
abnormal pain responses in patients with functional disorders. As medical interventions 
are common trigger events for functional disorders in the first place, the possibility of this 
intervention having negative effects on symptoms, or triggering new symptoms, may be an 
important consideration. 
 
In summary, the findings of this small study of a single session of supraliminal TMS in 
stable chronic outpatients who have already explored other treatment options are not 
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encouraging and suggest that some of the reported treatment effects from other studies 
may be the result of interactional processes between treating health professional and 
patient. However, TMS may have a helpful role as a part of a multidisciplinary 
rehabilitation programme, and in particular with patients who have severe deficits such as 
weakness, blindness or anaesthesia where reversibility of the symptom and therefore 
potential for improvement is hard to demonstrate in other ways.  
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